Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Tenecteplase for senvindu hjerneslag veiledet av DWI-FLAIR-mismatch (TRUST-MISMATCH)

5. november 2026 oppdatert av: Bo Song, The First Affiliated Hospital of Zhengzhou University

Tenecteplase trombolyse for akutt iskemisk hjerneslag i 4,5–9-timers vinduet veiledet av DWI-FLAIR-mismatch: En multikenter, prospektiv, randomisert, dobbeltblind, placebokontrollert studie

The goal of this clinical trial is to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in patients with acute ischemic stroke (AIS) guided by DWI-FLAIR mismatch on MRI. The main questions it aims to answer are:

  1. Does tenecteplase improve functional outcomes at 90 days compared with standard treatments in AIS patients administered 4.5-9 hours after stroke onset guided by DWI-FLAIR mismatch?
  2. The safety of tenecteplase thrombolysis for AIS patients in the 4.5-9 hours guided by DWI-FLAIR mismatch.

Researchers will compare tenecteplase to placebo to see if it is effective and safe for these patients.

Participants will be randomly assigned (1:1) immediately after randomization:

  • Tenecteplase group: received tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg).
  • Control group: aspirin (300 mg) plus tenecteplase placebo. From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Current clinical guidelines recommend intravenous thrombolysis (IVT) for eligible AIS patients within 4.5 hours of symptom onset. However, approximately 67 to 75% of patients present after 4.5 hours after stroke onset or with an unknown time of onset. CT perfusion (CTP) and perfusion-diffusion magnetic resonance imaging (MRI) have demonstrated that potentially viable brain tissue may persist beyond 4.5 hours after stroke onset. Recent trials, such as EXTEND, TRACE III, and the HOPE study, suggest that IVT can improve functional outcomes in AIS patients with salvageable brain tissue identified beyond 4.5 hours and up to 24 hours, using advanced perfusion imaging. Nonetheless, due to the high cost of perfusion software in developing countries, extended-window thrombolysis has not been widely implemented in many stroke centers. Therefore, it is crucial to develop alternative strategies to guide IVT in patients beyond 4.5 hours.

In recent years, the mismatch between a visible acute ischemic lesion on diffusion-weighted imaging (DWI) and the absence of a corresponding hyperintensity on fluid-attenuated inversion recovery (FLAIR) has been recognized as a predictor of symptom onset within 4.5 hours before imaging. The WAKE-UP trial demonstrated that among AIS patients with unknown time of onset (last known well >4.5 hours) and DWI-FLAIR mismatch, IVT administered within 4.5 hours after symptom recognition significantly improved functional outcomes. However, approximately 30% of AIS patients exhibit DWI-FLAIR mismatch between 4.5 and 9 hours after onset. Whether these patients can benefit from thrombolysis remains uncertain.

TRUST-MISMATCH is a multicenter, prospective, randomized, double-blind, placebo-controlled clinical. We want to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in AIS patients guided by DWI-FLAIR mismatch on MRI.

Studietype

Intervensjonell

Registrering (Antatt)

564

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Henan
      • Zhengzhou, Henan, Kina, 450052
        • Rekruttering
        • The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥ 18 years;

  2. AIS with symptom onset 4.5-9 hours before enrollment, including wake-up stroke and unwitnessed stroke (onset time defined as when symptoms were first noticed);

  3. Imaging criteria:

    1. DWI-FLAIR mismatch: visible lesion on DWI with no marked visible lesion on FLAIR;
    2. DWI infarct core not exceeding one-third of the middle cerebral artery territory, one-half of the anterior cerebral artery territory, or one-half of the posterior cerebral artery territory;
  4. NIHSS score 4-25;

  5. First-ever stroke or previous stroke without significant disability (pre-stroke mRS ≤ 1);

  6. Signed informed consent from the patient or legally authorized representative.

Exclusion Criteria:

  1. Planned endovascular treatment;
  2. Contradictory to MRI examination;
  3. MRI image not qualified for evaluation;
  4. Obvious head injuries or strokes within 3 months;
  5. Subarachnoid or intracranial hemorrhage;
  6. History of intracranial hemorrhage;
  7. Intracranial tumor, arteriovenous malformation or aneurysm;
  8. Intracranial or spinal cord surgery within 3 months;
  9. Active internal hemorrhage;
  10. platelet count of <100000/mm3;
  11. Aortic arch dissection;
  12. Heparin therapy within 24 hours;
  13. Oral warfarin is being taken and INR>1.6 or APTT abnormal;
  14. Oral anticoagulation therapy;
  15. Systolic pressure≥185 mmHg or diastolic pressure≥110 mmHg;
  16. Blood glucose < 50 mg/dl (2.7mmol/L);
  17. Pregnancy;
  18. Neurological deficit after epileptic seizures;
  19. Major surgery within 1 month;
  20. Gastrointestinal or urinary tract hemorrhage within the previous 30 days;
  21. Myocardial infarction within 3 months;
  22. Allergy to study drugs;
  23. Unlikely to adhere to the trial protocol or follow-up;
  24. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;
  25. Participation in other interventional clinical trials within the previous 3 months.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Tenecteplase group:

Patients will receive tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg) immediately after randomization.From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.

TNK-tPA (0.25 mg/kg, to maximum of 25mg)

Asprin (placebo)

TNK-tPA (placebo)

Aktiv komparator: Control group

Patients will receive asprin(300mg) plus intravenous TNK(placebo, 0.25mg/kg, a maximum of 25 mg) immediately after randomization. From day 2 to day 90, patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.

Asprin (placebo)

TNK-tPA (placebo)

Asprin (300mg)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Modified Rankin Scale (mRS)
Tidsramme: 90 ± 7 days

Proportion of subjects of excellent outcome defined as mRS (0-1) at 90 ± 7 days.

90 ± 7 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Modified Rankin Scale (mRS)
Tidsramme: 90 ± 7 days

Proportion of subjects of excellent outcome defined as mRS (0-2) at 90 ± 7 days.

90 ± 7 days
Modified Rankin Scale (mRS)
Tidsramme: 90 days

Ordinal shift analysis of mRS at 90 days

90 days
National Institutes of Health Stroke Scale (NIHSS)
Tidsramme: 72 hours and 7 ± 1 days (or at discharge)

Proportion of subjects with an improvement in NIHSS score of ≥2 points from baseline.

72 hours and 7 ± 1 days (or at discharge)
National Institutes of Health Stroke Scale (NIHSS)
Tidsramme: 72 hours and 7 ± 1 days (or at discharge)

Proportion of subjects achieving an NIHSS score of ≤1.

72 hours and 7 ± 1 days (or at discharge)
Barthel (BI)
Tidsramme: 90 ± 7 days

Barthel Index score at 90 ± 7 days.

90 ± 7 days
EuroQol 5-Dimension (EQ-5D)
Tidsramme: 90 ± 7 days

Quality of life measured by EQ-5D scale at 90 ± 7 days.

90 ± 7 days
Modified Rankin Scale (mRS)
Tidsramme: 90 ± 7 days
  1. Proportion of subjects of excellent outcome defined as mRS (0-2) at 90 ± 7 days.
  2. Ordinal distribution of mRS at 90 ± 7 days
90 ± 7 days

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Symptomatic intracranial hemorrhage (sICH)
Tidsramme: 36 hours

Proportion of subjects with symptomatic intracranial hemorrhage (sICH) within 36 hours (according to the ECASS III criteria for the primary safety analysis, with SITS-MOST and Heidelberg definitions used for supportive analyses).

36 hours
Death
Tidsramme: 90 days

Overall mortality rate at 90 days.

90 days
Systemic bleeding
Tidsramme: 90 days

Systemic bleeding at 90 days (according to the GUSTO criteria)

90 days
Adverse events (AEs)/ serious adverse events (SAEs)
Tidsramme: 90 ± 7 days

Proportion of patients with adverse events (AEs)/ serious adverse events (SAEs) within 90 ± 7 days.

90 ± 7 days
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Tidsramme: 90 ± 7 days

Proportion of subjects experiencing MACCE (defined as ischemic stroke, hemorrhagic stroke, transient ischemic attack, myocardial infarction, or vascular death).

90 ± 7 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studiestol: Bo Song, MD, Department of Neurology, the First Affiliated Hospital of Zhengzhou University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

2. november 2026

Primær fullføring (Antatt)

29. februar 2028

Studiet fullført (Antatt)

31. oktober 2028

Datoer for studieregistrering

Først innsendt

6. april 2026

Først innsendt som oppfylte QC-kriteriene

17. april 2026

Først lagt ut (Faktiske)

20. april 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • MISMATCH-001

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .